



Biotech Daily

Friday January 27, 2017

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ONCOSIL UP 18%, AIRXPANDERS DOWN 7%**
- * **AIRXPANDERS TO RAISE \$45m**
- * **PROF ALAN MACKAY-SIM AUSTRALIAN OF THE YEAR 2017**
- * **INNATE PLEADS SCHULTZ TO ASX 120% QUERY, NO TRUMPS**
- * **SUDA TAKES HC BERLIN PHARMA SETTLEMENT HALT TO SUSPENSION**
- * **NARELLE, ANDREW FAY TAKE 11% OF MEDICAL AUSTRALIA**
- * **COGSTATE APPOINTS JANE MCALOON DIRECTOR**

MARKET REPORT

The Australian stock market climbed 0.75 percent on Friday January 27, 2017 with the ASX200 up 42.5 points to 5,714.0 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 12 fell, 10 traded unchanged and three were untraded.

Oncosil was the best, up 1.6 cents or 18.0 percent to 10.5 cents with 2.3 million shares traded, followed by Dimerix up 14.3 percent to 0.8 cents with 100,000 shares traded and Living Cell up 10.5 percent to 10.5 cents with 1.96 million shares traded.

IDT climbed 5.6 percent; Ellex, Polynovo and Prana improved more than three percent; Genetic Signatures, Impedimed and Uscom rose more than two percent; Actinogen, Atcor, Factor Therapeutics and Sirtex were up more than one percent; with CSL and Mesoblast up by less than one percent.

Airxpanders led the falls, down 7.5 cents or seven percent to \$1.00 with 3.9 million shares traded.

Viralytics fell four percent; Benitec, Opthea and Pro Medicus were down more than three percent; Bionomics, Orthocell and Prima shed more than two percent; Neuren, Resmed and Starpharma were down more than one percent; with Clinuvel, Cochlear and Nanosonics down by less than one percent.

AIRXPANDERS

Airxpanders says it has commitments to raise \$45 million in a private placement to sophisticated and professional investors at 92 cents per Chess depository instrument. Airxpanders said that the funds would be used to build inventory for the US, accelerate investment for US sales and marketing, complete commercial manufacturing capacity expansion and for general working capital.

Airxpanders fell 7.5 cents or seven percent to \$1.00 with 3.9 million shares traded.

NATIONAL AUSTRALIA DAY COUNCIL

The National Australia Day Council says that the highest honor this year was awarded to Prof Mackay-Sim for his work on stem cells for treating spinal cord injuries.

The Council said that the Brisbane-based Griffith University's Prof Mackay-Sim was an "authority on the human sense of smell and the biology of nasal cells ... [and] led the world's first clinical trial using these cells in spinal cord injury".

The Council said that Prof Mackay-Sim's research helped play a central role in the world's first successful restoration of mobility in a quadriplegic man.

The National Australia Day Council said that Prof Mackay-Sim had been the director of the National Centre for Adult Stem Cell Research for a decade and the research used stem cells to understand the biological bases of brain disorders and diseases such as schizophrenia, Parkinson's disease and hereditary spastic paraplegia.

In accepting his award, Prof Mackay-Sim called for bipartisan support for biomedical research, including a call for 20-year funding rather than the current election-to-election-based funding.

INNATE IMMUNOTHERAPEUTICS

Innate has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 120.5 percent from 83 cents on December 22, 2016 to \$1.83 on January 25, 2017 and noted an increase in the trading volume.

In December, Innate similarly "pleaded Schultz" to the ASX asking for an explanation for a 47.8 percent increase to \$1.16 between December 20 and 30, 2016 (BD: Jan 22, 2017).

It was widely reported in January that people associated with US President Donald Trump had shares in the company, including major shareholder US Republican Representative Chris Collins, who has been a director of Innate since 2006.

Innate did not mention this in either ASX query, but today said that "in recent weeks there have been a number of media articles in the US that may have brought the company to the attention of new US investors".

"There have been similar reports in the Australian media which may also have generated increased interest in the company's prospects," Innate said.

Innate fell 35 cents or 19.8 percent \$1.42 with 2.5 million shares traded.

SUDA

Suda has requested a voluntary suspension to follow the trading halt requested on January 24, pending an "in relation to the settlement with the estate of HC Berlin Pharma" (BD: Jan 24, 2017).

Suda last traded at 2.3 cents.

MEDICAL AUSTRALIA

Narelle and Andrew Fay say they have increased their substantial holding in Medical Australia from 13,599,381 shares (9.94%) to 14,995,870 (10.96%).

The substantial shareholder notice said the Neutral Bay, Sydney-based Ms and Mr Fay bought shares between July 18, 2016 and January 25, 2017, with the largest acquisition 750,000 shares for \$33,750 or 4.5 cents a share on August 5, 2016.

Medical Australia was untraded at 4.6 cents.

COGSTATE

Cogstate says it has appointed Jane McAloon as an independent non-executive director. Cogstate said that until mid-2015, Ms McAloon was part of mining company BHP Billiton's group management committee, having been company secretary from 2007.

The company said that prior to joining BHP Billiton in 2006, Ms McAloon was an executive at energy company AGL and was currently a non-executive director of Healthscope and Energy Australia.

Cogstate said that previously Ms McAloon was the director-general of the New South Wales Ministry of Energy and Utilities, deputy director-general of the New South Wales Cabinet Office and held executive roles in Rail, Land & Water Conservation and Forestry and previously worked in private legal practice.

The company said that Ms McAloon held Bachelor of Economics and Bachelor of Laws degrees from Monash University and a Graduate Diploma in Applied Corporate Governance.

Cogstate climbed six cents or 4.8 percent to \$1.30.